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Abstract : Purρose/Objectives : This study was conducted to assess the feasibility and efficacy 
of definitive radiotherapy (RT) with a total dose of 66 Gy and concurrent carboplatin-paclitaxel 
chemotherapy for patients (pts) with stage m non-small celllung cancer 
Materials/Methods Between April 2007 and Dec巴mber2013， 99 pts with non-small cel lung 
cancer were treated using RT with concurrent carboplatin-paclitaxel chemotherapy in our 
hospital. Sixty-eight of them received RT with a total dose of 66 Gy. We analyzed 46 Stage m 
pts who had been treated with RT using three-dimensional radiotherapy treatment planning. 
The prophylactic mediastinal lymph nodes were included in the clinical target volume for RT. 
The survival rate after the start of RT was estimated using the Kaplan-Meier method. We 
estimated the cumulative local failure and distant metastasis rates with the Fine-Gray method. 
Adverse events were evaluated according to the CTCAE (v.4.0) . 
Results The median age of the pts was 70.9 (52.8-78.7) years old (y.o) . The performance 
status (PS) of each pt was fairly good (ECOG PS 0: 25， PS 1: 20， PS3:1) ， and their clinical 
stages (UICC 7th) were twenty-nine m A and seventeen m B. Diagnoses were pathologicaly 
confirmed in 32 pts. The median follow-up period was 35.7 (2.0-82.2) months among al pts， 
and 55.9 (40.1-82.2) months among survivors. The 3-and 5-year Kaplan-Meier overall survival 
rates were 52.2 and 34.0%， respectively， and the median survival time was 36.6 months. The 3-
and 5-year Kaplan-Meier progression-free survival rates were 29.1 and 21.9%， respectively， and 
the median progression-free survival time was 9.9 months. The 5-year local failure rate was 
37.6%， and the 5-year distant metastasis rate was 49.7%. Sixteen (34.8%) pts required steroid 
administration because of radiation pneumonitis (CTCAE Grade 2 or higher) and two of them 
died (Grade 5) . No other severe non-hematologic toxicity (Grade 3 or higher) was observed. 
Conclusion: These results suggest that definitive RT with a total dose of 66 Gy and concurrent 
carboplatin-paclitaxel chemotherapy is feasible and may be promising for pts with Stage m non-
smal cel lung cancer. 
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Key words: Non-small c巴1lung cancer， Concurrent chemoradiotherapy， 66 Gy， Carboplatin-
paclitaxel chemotherapy 
Introduction 
Stage rn non-small cel lung cancer patients have a poor prognosis despite recent advances 
in surgery and chemoradiotherapy. According to Cancer Research UK、shomepage!) ， the five-
year survival rates for stage rn A and m B are 19-24 and 7-9%， respectively. The standard 
therapy for inoperative stage rn non-small cel lung cancer is chemoradiotherapy. The most 
common radiation dose in chemoradiotherapy for such patients (pts) is60-63 Gy， given in 
1.8-2.0-Gy fractions. Otherwise， the standard dose of definitive radiotherapy (RT) alone for 
non-small cel lung cancer is 60-70 Gy， given in 1.8-2.0-Gy fractions. A recent studl) showed 
凶atthe outcome of 74 Gy in 2-Gy fractions for concurrent chemoradioth巴rapywas not better 
than that of 60 Gy. The most suitable or optimized radiation dose in chemoradiotherapy for 
non-small celllung cancer has yet to be established. 
In our institution， we use definitive RT with a total dose of 66 Gy and concurrent carboplatin-
paclitaxel chemoth巴rapyfor relatively elderly or impaired-status pts with stage rn non-small 
celllung cancer to achieve relatively better outcomes while considering their quality of life at 
the same time. 
This retrospective study was conducted to assess the feasibility and eficacy of definitive RT 
with a total dose of 66 Gy and concurrent carboplatin-paclitaxel chemotherapy 
Methods and Materials 
Between April 2007 and December 2013， 99 pts with non-small cel lung cancer were treated 
using RT with concurrent carboplatin-paclitaxel chemotherapy in our hospital. The total 
radiation dose consisted of 48 Gy (one pt who discontinued RT because of Grade 2 radiation 
pneumonitis) ，60 Gy (16 pts) ，62 Gy (one pt) ，63.4 Gy (one pt) ，64 Gy (11 pts) ，66 Gy (68 
pts) ，and 70 Gy (one pt) . Excluding 13 postoperative pts， 55 pts received RT with a total dose 
of 66 Gy:five IlA and three Il B， twenty-nine rn A， seventeen rn B， and on巴 Nbased on the 
UICC staging system (7th edition) . 
In this study， we analyzed 46 pts with stage rn who had been treated with conventional RT 
using three-dimensional radiotherapy treatment planning. The gross tumor volume for RT was 
defined as the primary tumor and regionally involved lymph nodes on CT (>1 cm short a玄is). 
Prophylactic iradiation of the mediastinal lymph nodes was performed and the radiation fields 
were included in the clinical target volume for RT. For most pts， we used the anterior-posterior 
and posterior-anterior paralel opposed (AP & PA) field technique followed by an oblique 
opposed field technique to reduce the dose to the spinal cord. We chose the dose of field changes 
(from AP & PA to oblique) after 40， 42， or 44 Gy for each pt， considering the length of the 
spinal cord in each radiation field and volume of the lung receiving at least 20 Gy (V20) . RT 
was given 5 days per week in 2-Gy fractions daily using 6-or lQ-MV X-rays. We prescribed 
66 Gy as the planning target volume for RT 
66 GY & CARBOPLATIN-P ACLIT AXEL FOR LUNG CANCER (3) 
In the concurrent carboplatin-paclitaxel chemotherapy， pts were scheduled to receive 6 cycles 
of carboplatin (area under curve 2) and paclitaxel (40 mg/rri) administered intravenously once 
a week. The criteria for starting treatment were as follows: absolute white blood cel count of 
3，000 cells perμL or higher， platelet count of 100，000 cels perμL or higher. Th巴criteriafor 
continuous administration were as follows: absolute white blood cel count of 3，000 cels perμL 
or higher， platelet count of 75，000 cels perμL or higher 
Overall and progression-free survival rates after the beginning of RT were estimated 
using the Kaplan-M巴iermethod， compared with the log-rank test， and modeled with the Cox 
proportional hazards method. We estimated th巴cumulativelocal failure (including loco-regional 
failure outside the radiation field) and distant metastasis rates with the Fine-Gray method. In 
our analyses， dropout cases were regarded as mortality. We compar巴dcontinuous data with t-
tests. All analyses were done with EZR3) on R commander (ver 01.32) . Adverse events were 
evaluated according to the CTCAE (v.4.0) . 
Results 
The median age of the forty-six pts was 70.9 (52.8-78.7) years old (y.o.). The performance 
status (PS) of each pt was satisfactory (ECOG PS 0: 25， PS 1: 20， PS 3: 1)， and the clinical 
stages (UICC 7th) consisted of twenty-nine m A and seventeen m B. Diagnoses were 
pathologically confirmed in 32 pts (22 squamous cel carcinomas， 8 adenocarcinomas， one 
large cel carcinoma， and one mucoepidermoid carcinoma) (Table 1). The other 14 pts were 
diagnosed radiographically and on considering other clinical factors. Other patient characteristics 
are also shown in Table 1. 
There were four courses of the concurrent carboplatin-paclitaxel chemotherapy in 4 cases， 
five courses in 14， and six courses in 28. 
The median follow-up period was 35.7 (2.0-82.2) months among al pts， and 55.9 (40.1-82.2) 
months among survivors. The 3-and 5-year Kaplan-Meier overall survival rates were 52.2 
(95% CI 37.0-65.4) % and 34.0 (95% CI 20.1-48.5) %， respectively， and the median survival time 
was 36.6 (95% CI 18.9-50.3) months (Fig. 1). We compared the di鉦erencesbetween each of 
the following pairs: aged over 71 or not. PS 0 or not， Stage m A or m B， and squamous cel 
carcinoma or not. using the log-rank test. but no significant di笠erencewas identified. 
The 3-and 5-year Kaplan-Meier progression-free survival rates were 29.1 (95% CI 
16.8-42.7) % and 21.9 (95% CI 10.2-36.3) %， respectively， and the median progression-free 
survival time was 9.9 (95% CI 4.9-15.4) months (Fig. 2) . The 5-year local failure rate was 
37.6 (95% CI 22.5-52.7) % (Fig. 3) ， and the 5-year distant metastasis rate was 49.7 (95% CI 
33.8-63.7) % (Fig. 4) . 
As for adverse events， sixteen (34.8%) pts required steroid administration because of 
radiation pneumonitis (CTCAE Grade 2 or higher) and two (4.3%) pts died (CTCAE Grade 5). 
No other severe non-hematologic toxicity (Grade 3 or higher) was observed. 
We analyzed only 15 pts' dose-volume histograms because the radiation treatment planning 
system in our institute was b巴ingchanged. The median lung volume receiving at least 5 Gy 
(V5) ， V20， and mean lung dose were 32.3 (20.7-43.8) %， 26.4 (15.8-37.0) %， and 15.9 (9.9-21.1) 
(4) 
Table 1. Patient Characteristics 
Age 
Median (range) 
Sex 
Kazuya INOUE et al. 
70.9 (52.8-78.7) 
Men 42 (91%) 
4 (9%) Women 
ECOG performance status 。
2 
3 
Smoking history 
Non-smoker 
Former smoker 
Current 
Unknown 
Histology (32 pts) 
Squamous cel carcinoma 
Adenocarcinoma 
Large cel carcinoma 
Mucoepidermoid carcinoma 
stage (UICC 7出
illA 
illB 
TωICC 7也)
25 (54%) 
20 (44%) 
0(0%) 
1 (2%) 
3 (7%) 
25 (54%) 
14 (30%) 
4 (9%) 
22 (69%) 
8 (25%) 
1 (3%) 
1 (3%) 
29 (63%) 
17 (37%) 
2 
3 
4 
N (UICC 7th) 
0 
1 
2 
3 
8 (17%) 
14 (30%) 
9 (20%) 
15 (33%) 
1 (2%) 
5 (11%) 
28 (61%) 
12 (26%) 
Table 2. Summary of the outcomes 
Overall s岨rvival
Dead 
3-year 
5-year 
Median (months) 
Progression-free survival 
Fail 
3-ye紅
5-ye釘
Median (months) 
Local failure 
Fail 
2-ye紅
3-year 
5-year 
Distant metastasis 
29 
52.2% (37.0-65.4) 
34.0% (2且1-48.5)
3ι6 (18.9-50.3) 
34 
29.1 % (16.8-42.7) 
21.9% (10.2-36.3) 
9.9 (4.9-15.4) 
16 
24.5% (13.0-37.9) 
31.2% (18.2-45.l) 
37.6% (22.5-52.7) 
Occurrence 
2-year 
3-year 
5-ye町
22 
42.2% (27.5-56.2) 
46.7% (31.5-60.6) 
49.7% (33.8-63.7) 
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Fig.l Overall survival 
The 3-and 5-ye訂 Kaplan-Meieroverall survival 
rates were 52.2% and 34.0 %， respectively. 
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Fig. 2. Progression-free survival 
The 3-and 5-year Kaplan-νieier progression-free 
survival rates were 29.1 % and 21.9%， respectively， 
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Fig. 3. Local failure 
The 5-year local failure rate was 37.6 % 
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Fig. 4. Distant metastasis 
The !:トyeardistant metastasis rate was 49.7% 
66 GY & CARBOPLATIN-PACLITAXEL FOR LUNG CANCER (5) 
Gy， respectively. Those pts included one with Grade 5 radiation pneumonitis. This pt had the 
largest V5 (43.8%) ， V20 (37.0%) ，and mean lung dose (21.1 Gy) . We analyzed V5， V20， and 
the mean lung dose of the cases with and without radiation pneumonitis with t-tests， but no 
significant difference was identified. 
Discussion 
A previous randomized phase 3 study2) showed a median overall survival of 28.7 months 
(95% CI 24.1-36.9) for patients who received 60-Gy radiotherapy with concurrent carboplatin-
paclitaxel chemotherapy. Another phase 2 studl) indicated a median overall survival of 110 
weeks (95% CI 90-184) for patients who received 60-Gy radiotherapy with concurrent weekly 
paclitaxel plus carboplatin. Our results showed a median overall survival of 36.6 months (95% 
CI 18.9-50.3) for patients who received 66-Gy radiotherapy with the same concurrent regimen 
of chemotherapy. 
Regarding progression-free survival. a randomized phase 3 study2) showed that median 
survival was 11.8 months (95% CI 10.2-14.3) for patients who received 60 Gy and a phase 2 
study4) indicated 46 weeks (95% CI 31-64) . Our result was 9.9 months (95% CI 4.9-15.4) 
Concerning local failure and distant metastasis， the randomized phase 3 study above2) used 
the same Fine-Gray method for statistical analysis， and showed a 2-year local failure rate 
of 30.7% (95% CI 24.5-36.9) and 2-year distant metastasis rate of 46.6% (95% CI 39.9-53.4) 
for patients who had received 60 Gy. Our results show a local failure rate of 24.5% (95%CI 
13.0-37.9) and distant metastasis rate of 42.2% (95%CI27.5-56.2) in the same years (Table 2) . 
Our results suggest better overall survival and local control rates， and slightly better distant 
metastasis control. although our study was retrospective and observational and several biases 
may have affected the outcomes; however， most of the pts were elderly. A dose increase within 
the normal clinical dose range may improve the outcome of chemoradiotherapy for Stage m 
non-small cel lung cancer. Two phase 2 studies5l 6) on definitive radiotherapy with concurrent 
nab-paclitaxel plus carboplatin for Stage m non-small cel lung cancer were reported. One 
studl) 's dose was 60 Gy， and the other study6l 'swas 66 Gy. These two studies' mature data 
may provide useful references. 
Other previous reports7l8) suggested that definitive radiotherapy with concurrent carboplatin-
paclitaxel chemotherapy caused more frequent radiation pneumonitis than the cisplatin-
etoposide regimen. Another recent research9) showed Grade 3-4 (CTCAE v3.0) and Grade 5 
radiation pneumonitis was 9% and 1% among 107 pts with concurrent carboplatin-paclitaxel 
chemotherapy (60-66 Gy) for Stage m non-smal cel lung cancer， respectively. In our study， 
sixteen (34.8%) pts required steroid administration because of radiation pneumonitis (grade 
2 or higher) and two (4.3%) pts died (Grade 5) . No other severe non-hematologic toxicity 
(Grade 3 or higher) was observed. Fatal radiation pneumonitis may have been slightly more 
frequent， but adverse events may be acceptable in general. International individual patient 
data meta-analysis7) showed an overal rate of symptomatic pneumonitis of 29.8%， with fatal 
pneumonitis of 1.9%， and V20 (OR 1.09 per 1% incr巴ase，p=0.044) was found to be associated 
with fatal pneumonitis. One pt with a fatal outcome among 15 pts subjected to dose-volume 
(6) Kazuya INOUE et al. 
histogram analysis had the largest V20. In radiotherapy with concurrent carboplatin-paclitaxel 
chemotherapy. we need to take particular care to minimize the dose to the normal lung. 
In conclusion. this study suggests that definitive radiotherapy with a total dose of 66 Gy and 
concurrent carboplatin-paclitaxel chemotherapy is feasible and might be promising for pts with 
Stage m non-small c巴Ilung cancer. A prospective study is needed to confirm our results. 
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